Blueprint Medicines (BPMC) PT Raised to $115 at Wedbush
- Wall Street falls as Amazon earnings disappoint
- Amazon (AMZN) Plunges After Missing Sales and Guidance Expectations, Analysts Slash PTs to Reflect Weaker Guidance
- Pinterest (PINS) Tops Profit and Sales Views, But Shares Plunges Over 20% on a Big Monthly User Miss to Prompt Two Downgrades
- Bullard: Fed should taper this fall, go "fairly rapidly" to end early 2022
- Qualtrics International (XM) to Acquire Clarabridge
Wedbush analyst David Nierengarten raised the price target on Blueprint Medicines (NASDAQ: BPMC) to $115.00 (from $102.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Blueprint Medicines (BPMC) PT Raised to $147 at Goldman Sachs, Following Earnings
- Atos SE (ATO:FP) (AEXAY) PT Lowered to EUR40 at Deutsche Bank
- Blueprint Medicines Reports Second Quarter 2021 Financial Results
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!